Hypoxia-Inducible Factor (HIF)-1 Regulatory Pathway and Its Potential for Therapeutic Intervention in Malignancy and Ischemia

Overview

Journal Yale J Biol Med

Specialty Biology

Date 2007 Dec 28

PMID 18160990

Citations 267

Authors

Jennifer E Ziello

Ion S Jovin

Yan Huang

Affiliations

Soon will be listed here.

Abstract

Hypoxia-Inducible Factor (HIF)-1 is a dimeric protein complex that plays an integral role in the body's response to low oxygen concentrations, or hypoxia. HIF-1 is among the primary genes involved in the homeostatic process, which can increase vascularization in hypoxic areas such as localized ischemia and tumors. It is a transcription factor for dozens of target genes; HIF-1 is also essential for immunological responses and is a crucial physiological regulator of homeostasis, vascularization, and anaerobic metabolism. Furthermore, HIF-1 is increasingly studied because of its perceived therapeutic potential. As it causes angiogenesis, enhancement of this gene within ischemic patients could promote the vessel proliferation needed for oxygenation. In contrast, as HIF-1 allows for survival and proliferation of cancerous cells due to its angiogenic properties, inhibition potentially could prevent the spread of cancer. With a growing understanding of the HIF-1 pathway, the inhibition and stimulation of its transcriptional activity via small molecules is now an attractive goal. Gene therapy to achieve both vessel proliferation and tumor regression has been demonstrated in animal studies but requires significant improvement and modification before becoming commercially available. This review focuses on the potential of the HIF-1 pathway in therapeutic intervention for the treatment of diseases such as cancer and ischemia.

Citing Articles

Fascia-derived stem cells enhance fat graft retention by promoting vascularization through the HMOX1-HIF-1α pathway.

Chen G, Long J, Zhang Y, Zhou X, Gao B, Qin Z Stem Cell Res Ther. 2025; 16(1):92.

PMID: 40001185 PMC: 11863534. DOI: 10.1186/s13287-025-04204-w.

Protective effect of Pinacidil on hypoxic-reoxygenated cardiomyocytes in vitro and in vivo via HIF-1α/HRE pathway.

Wang Y, Wang J, Chen L, Zhou W, He H, Chen X PLoS One. 2025; 20(2):e0318859.

PMID: 39992983 PMC: 11849820. DOI: 10.1371/journal.pone.0318859.

Targeting Mitochondrial Dysfunction in Cerebral Ischemia: Advances in Pharmacological Interventions.

Belenichev I, Popazova O, Bukhtiyarova N, Ryzhenko V, Pavlov S, Suprun E Antioxidants (Basel). 2025; 14(1).

PMID: 39857442 PMC: 11760872. DOI: 10.3390/antiox14010108.

Complexed hyaluronic acid-based nanoparticles in cancer therapy and diagnosis: Research trends by natural language processing.

Umar A, Limpikirati P, Rivai B, Ardiansah I, Sriwidodo S, Luckanagul J Heliyon. 2025; 11(1):e41246.

PMID: 39811313 PMC: 11729671. DOI: 10.1016/j.heliyon.2024.e41246.

Discovery of Glucose Metabolism-Associated Genes in Neuropathic Pain: Insights from Bioinformatics.

Yu Y, Cheung Y, Cheung C Int J Mol Sci. 2025; 25(24.

PMID: 39769264 PMC: 11679926. DOI: 10.3390/ijms252413503.

References

Huang L, Gu J, Schau M, BUNN H . Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A. 1998; 95(14):7987-92. PMC: 20916. DOI: 10.1073/pnas.95.14.7987. View

Chapman-Smith A, Lutwyche J, Whitelaw M . Contribution of the Per/Arnt/Sim (PAS) domains to DNA binding by the basic helix-loop-helix PAS transcriptional regulators. J Biol Chem. 2003; 279(7):5353-62. DOI: 10.1074/jbc.M310041200. View

Jensen R, Ragel B, Whang K, Gillespie D . Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neurooncol. 2006; 78(3):233-47. DOI: 10.1007/s11060-005-9103-z. View

Vaupel P . The role of hypoxia-induced factors in tumor progression. Oncologist. 2004; 9 Suppl 5:10-7. DOI: 10.1634/theoncologist.9-90005-10. View

Lakhani N, Sarkar M, Venitz J, Figg W . 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy. 2003; 23(2):165-72. DOI: 10.1592/phco.23.2.165.32088. View

Tan C, de Noronha R, Roecker A, Pyrzynska B, Khwaja F, Zhang Z . Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. 2005; 65(2):605-12. View

Zagzag D, Zhong H, Scalzitti J, Laughner E, Simons J, Semenza G . Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer. 2000; 88(11):2606-18. View

Carmeliet P, Dor Y, Herbert J, Fukumura D, Brusselmans K, Dewerchin M . Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998; 394(6692):485-90. DOI: 10.1038/28867. View

Dery M, Michaud M, Richard D . Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol. 2004; 37(3):535-40. DOI: 10.1016/j.biocel.2004.08.012. View

10.

Trentin D, Hall H, Wechsler S, Hubbell J . Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1alpha variant for local induction of angiogenesis. Proc Natl Acad Sci U S A. 2006; 103(8):2506-11. PMC: 1413769. DOI: 10.1073/pnas.0505964102. View

11.

Kido M, Du L, Sullivan C, Li X, Deutsch R, Jamieson S . Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol. 2005; 46(11):2116-24. DOI: 10.1016/j.jacc.2005.08.045. View

12.

Belozerov V, Van Meir E . Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs. 2005; 16(9):901-9. DOI: 10.1097/01.cad.0000180116.85912.69. View

13.

Govindan R, Mcleod H, Mantravadi P, Fineberg N, Helft P, Kesler K . Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. Oncology (Williston Park). 2005; 18(14 Suppl 14):18-21. View

14.

Doronzo G, Russo I, Mattiello L, Riganti C, Anfossi G, Trovati M . Insulin activates hypoxia-inducible factor-1alpha in human and rat vascular smooth muscle cells via phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways: impairment in insulin resistance owing to defects in insulin signalling. Diabetologia. 2006; 49(5):1049-63. DOI: 10.1007/s00125-006-0156-0. View

15.

Vincent K, Shyu K, Luo Y, Magner M, Tio R, Jiang C . Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation. 2000; 102(18):2255-61. DOI: 10.1161/01.cir.102.18.2255. View

16.

Richard D, Berra E, Pouyssegur J . Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem. 2000; 275(35):26765-71. DOI: 10.1074/jbc.M003325200. View

17.

Natarajan R, Salloum F, Fisher B, Kukreja R, Fowler 3rd A . Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circ Res. 2005; 98(1):133-40. DOI: 10.1161/01.RES.0000197816.63513.27. View

18.

Knowles H, Raval R, Harris A, Ratcliffe P . Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res. 2003; 63(8):1764-8. View

19.

Mole D, Maxwell P, Pugh C, Ratcliffe P . Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing. IUBMB Life. 2002; 52(1-2):43-7. DOI: 10.1080/15216540252774757. View

20.

Kasper L, Boussouar F, Boyd K, Xu W, Biesen M, Rehg J . Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression. EMBO J. 2005; 24(22):3846-58. PMC: 1283945. DOI: 10.1038/sj.emboj.7600846. View